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Abstract
Existing methods for phenotypic selection of genetically modified mammalian cells suffer disadvantages of time, cost and
scalability and, where antibodies are used to bind exogenous cell surface markers for magnetic selection, typically yield cells
coated with antibody-antigen complexes and beads. To overcome these limitations we have developed a method termed
Antibody-Free Magnetic Cell Sorting in which the 38 amino acid Streptavidin Binding Peptide (SBP) is displayed at the cell
surface by the truncated Low Affinity Nerve Growth Receptor (LNGFRF) and used as an affinity tag for one-step selection
with streptavidin-conjugated magnetic beads. Cells are released through competition with the naturally occurring vitamin
biotin, free of either beads or antibody-antigen complexes and ready for culture or use in downstream applications.
Antibody-Free Magnetic Cell Sorting is a rapid, cost-effective, scalable method of magnetic selection applicable to either
viral transduction or transient transfection of cell lines or primary cells. We have optimised the system for enrichment of
primary human CD4+ T cells expressing shRNAs and exogenous genes of interest to purities of .99%, and used it to isolate
cells following Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 genome editing.
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Introduction
Pure populations of transfected or transduced mammalian cells
are commonly isolated from mixed samples by co-expression of
the gene or shRNA of interest with three sorts of phenotypic
marker: an exogenous gene encoding drug or antibiotic resistance;
an internal fluorescent protein, such as GFP, enabling Fluores-
cence-Activated Cell Sorting (FACS); or a cell surface protein
combined with antibody labelling. Where antibody labelling of a
cell surface marker is used, antibodies may be either conjugated to
a fluorochrome for FACS, or to biotin for affinity purification
using a solid streptavidin-conjugated matrix, typically magnetic
beads [1]. Compared with FACS, immunomagnetic selection is
relatively fast, simple and scalable for simultaneous processing of
multiple samples and large cell numbers [1,2]. It is supported by a
number of widely used commercial systems [3,4] including specific
product lines for the enrichment of cells using exogenous CD4, H-
2k or LNGFR (MACSelect; Miltenyi) or a membrane-targeted
mCherry fusion protein (CherryPicker; Clontech) as the cell
surface marker for antibody labelling.
Following immunomagnetic selection, cells typically remain
coated with magnetic beads and antibody-antigen complexes,
risking alteration of their behaviour or viability through cross-
linking of cell-surface receptors (triggering signalling) or internal-
isation of the ferrous beads (leading to toxicity) [5,6,7,8]. Methods
have therefore been devised to release the beads through use of a
low affinity biotin, cleavage of a nucleic acid linker, or competition
with a selected Fab (antigen-binding) antibody fragment [4]. These
approaches are limited, however, by requirements for additional
individualised reagents and/or leave cells coated with residual
antibody-antigen complexes.
Streptavidin-binding peptide tags with nanomolar dissociation
constants for streptavidin have been generated for the purification
of recombinant proteins [9,10,11]. We reasoned that expression of
a cell surface streptavidin-binding peptide tag could be used to
select cells co-expressing a gene or shRNA of interest by binding
directly to streptavidin beads, without the need for antibody
labelling. Furthermore, selected cells could subsequently be
released from the beads by incubation with biotin, a naturally
occurring vitamin already present in many cell culture media,
leaving cells free of antibody and beads (Figure 1A). In this report
we demonstrate the feasibility of this approach, which we term
Antibody-Free Magnetic Cell Sorting, and show that it can be
used to obtain genetically modified primary human CD4+ T cells
at a purity of .99%. Finally, we adapt the technique for the
enrichment of cells following CRISPR/Cas9 genome editing.
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Materials and Methods
Ethics statement
Ethical permission for this project was granted by the
Cambridgeshire 2 Research Ethics Committee (REC reference
97/092). Informed written consent was obtained from all of the
volunteers included in this study prior to providing blood samples.
Antibodies and reagents
The following fluorescent conjugates were used for flow
cytometry: ME20.4 anti-LNGFR-PE/APC (BioLegend); BB7.2
anti-HLA-A2-PE (BioLegend); W6/32 anti-MHC-I-AF647 (Bio-
Legend); FN50 anti-CD69-APC (BioLegend); and streptavidin-
APC (eBioscience). Bovine Serum Albumin (BSA) Cohn fraction V
(A4503; Sigma) which does not contain free biotin was used for
Antibody-Free Magnetic Cell Sorting.
Cell culture
HEK 293 T cells (293Ts) were cultured in DMEM supple-
mented with 10% FCS and 1% penicillin/streptomycin. Primary
human CD4+ T cells were isolated from peripheral blood by
density gradient centrifugation using Lympholyte-H (Cedarlane
Laboratories) followed by negative selection with the Dynabeads
Untouched Human CD4 T Cells Kit (Invitrogen) according to the
manufacturer’s instructions. Cells were cultured in RPMI-1640
supplemented with 10% FCS and 1% penicillin/streptomycin and
activated within 48 hrs using Dynabeads Human T-Activator
CD3/CD28 beads (Invitrogen) according to the manufacturer’s
instructions. Purity was assessed by flow cytometry for CD3 and
CD4 and typically found to be $95%.
Plasmids
The lentiviral expression construct pHRSIN-HA-HLA-A2
(encoding HLA-A2 with an N-terminal HA tag and a murine
immunoglobulin signal peptide) has been previously described
[12]. Overlapping DNA oligomers encoding the 38 amino acid
SBP [10,11] were synthesised (Sigma), ligated and inserted using
EcoRI/XhoI sites to generate pHRSIN-HA-SBP-HLA-A2. The
truncated LNGFR was then amplified by PCR from the retroviral
vector pZLRS-IRES-DLNGFR [13] and inserted using XhoI/
NotI sites in place of HLA-A2 to generate the pHRSIN-HA-SBP-
DLNGFR construct utilised for pilot experiments in 293Ts
(Figure 1).
To generate bicistronic lentiviral vectors (Figures 2–4), a codon-
optimised SBP-DLNGFR fusion protein construct was synthesised
in pUC57 (Genscript). For co-expression with an exogenous gene
of interest, this construct was subcloned into a self-inactivating
lentiviral vector derived from pHRSIN-cPPT-SEW kindly pro-
vided by Yasuhiro Ikeda [14] to generate pHRSIN-SE-PGK-SBP-
DLNGFR-W (encoding SFFV-EGFP and PGK-SBP-DLNGFR
with a distal WPRE). The PGK promoter was replaced with a
Porcine teschovirus-1 2A (P2A) sequence [15] synthesised in
Figure 1. SBP-DLNGFR cell surface affinity tag for Antibody-Free Magnetic Cell Sorting. In Antibody-Free Magnetic Cell Sorting (A)
transfected or transduced cells co-express a gene or shRNA of interest with a streptavidin-binding cell surface affinity tag. Cells are selected by
incubation with streptavidin-conjugated beads then, after washing to remove unbound cells, released by incubation with excess biotin. SBP-DLNGFR
comprises the 38 amino acid SBP fused to the N-terminus of the truncated LNGFR (B). Expression of SBP-DLNGFR at the cell surface was tested 48 hrs
after transient transfection of 293Ts with pHRSIN-HA-SBP-DLNGFR by staining with streptavidin-APC (C). After a further 72 hrs, cells expressing SBP-
DLNGFR were selected from the bulk population using magnetic streptavidin-conjugated beads: (i) Dynabeads Biotin Binder (Invitrogen) or (ii)
Streptavidin MicroBeads (Miltenyi) (D). Purity of transfected cells before (black) and after (red) selection was assessed by staining with anti-LNGFR-PE.
Background staining of cells transfected with a control vector is shown (grey).
doi:10.1371/journal.pone.0111437.g001
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pUC57 (Genscript) to generate pHRSIN-SE-P2A-SBP-DLNGFR-
W. BamHI and NotI sites flanking EGFP allow substitution of
alternative Genes Of Interest for cotranslation as GOI-P2A-SBP-
DLNGFR.
For co-expression with an shRNA of interest, the SBP-
DLNGFR construct was subcloned into a self-inactivating
lentiviral vector derived from pCSRQ kindly provided by Greg
Towers [16] to generate pHRSIREN-PGK-SBP-DLNGFR-W
(encoding a U6-shRNA cassette and PGK-SBP-DLNGFR with a
distal WPRE). The PGK promoter was replaced with an SFFV
promoter PCR-amplified from pHRSIN-cPPT-SEW to generate
pHRSIREN-S-SBP-DLNGFR-W. BamHI and EcoRI sites allow
insertion of alternative shRNAs of interest into the U6-shRNA
cassette as described for the pSIREN-RetroQ vector (Clontech).
For CRISPR/Cas9 genome editing, P2A-SBP-DLNGFR was
subcloned from pHRSIN-SE-P2A-SBP-DLNGFR-W into
pSpCas9(BB)-2A-Puro (PX459; Addgene) to generate
pSpCas9(BB)-P2A-SBP-DLNGFR (encoding a U6-guide RNA
(gRNA) cassette and human codon-optimized S. pyogenes Cas9
(SpCas9) co-translated with SBP-DLNGFR via a P2A peptide
linker). BbsI sites allow insertion of site-specific gRNAs identified
using the CRISPR Design Tool (http://crispr.mit.edu) [17]
according to protocols kindly made available by Feng Zhang
(http://www.genome-engineering.org) [18].
The final nucleotide and amino acid sequences of the codon-
optimised SBP-DLNGFR construct are shown (Sequence S1). For
knockdown of b2-microglobulin (b2 m), the following shRNA
target sequence was used: 59-GAATGGAGAGAGAATTGAA-39
[12]. For knockout of b2 m, the following gRNA target sequence
was kindly selected and subcloned by Dick van den Boomen: 59-
GGCCGAGATGTCTCGCTCCG-39. For functional assays in
primary human CD4+ T cells, the following control (non-
targeting) shRNA sequence was kindly provided by Greg Towers:
59-GTTATAGGCTCGCAAAAGG-39.
Transfection and lentiviral transduction
FuGENE 6 (Promega; lentiviral production) or TransIT-293
(Mirus; general transfections) were used for plasmid DNA
transfections in 293Ts. To generate pseudotyped lentiviral stocks,
293Ts were co-transfected with pHRSIN2/pHRSIREN-based
lentivector, pCMVR8.91 and pMD.G, media changed at 24 hrs
and viral supernatant harvested and filtered (0.45 mm) at 48 hrs
prior to concentration using Lenti-X Concentrator (Clontech) or
storage at –80uC. Transduction of primary human CD4+ T cells
Figure 2. Phenotypic selection using SBP-DLNGFR. 293Ts were transiently transfected or lentivirally transduced with pHRSIN-SE-PGK-SBP-
DLNGFR-W (encoding EGFP and SBP-DLNGFR; A) or pHRSIREN/b2 m-PGK-SBP-DLNGFR-W (encoding shRNA to b2 m and SBP-DLNGFR; B) and stained
with streptavidin-APC plus/minus anti-HLA-A2-PE. Transfected/transduced cells are either GFP+/streptavidin-APC+ or HLA-A2-low/streptavidin-APC+
(dashed circles). Primary human CD4+ T cells were lentivirally transduced with the same constructs then selected using Dynabeads Biotin Binder.
Purity of cells before (green or blue) and after (red) selection was assessed by GFP fluorescence (C) or staining with anti-HLA-A2-PE (D). Transduced
cells are either GFP+ or HLA-A2-low (dashed boxes). Background staining of untransfected/unstransduced controls is shown (grey).
doi:10.1371/journal.pone.0111437.g002
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Figure 3. Optimised Antibody Free Magnetic Cell Sorting of primary human CD4+ T cells. Primary human CD4+ T cells were lentivirally
transduced with pHRSIREN/b2 m-PGK-SBP-DLNGFR-W (encoding shRNA to b2 m and SBP-DLNGFR under the PGK promoter) and either rested for 2
weeks (pale blue) or re-stimulated with CD3/CD28 Dynabeads 3 days prior to analysis (dark blue). Cells were co-stained with anti-HLA-A2-PE and anti-
LNGFR-APC, and expression levels of SBP-DLNGFR compared in HLA-A2-low cells (A). Transduction with pHRSIN-SE-PGK-SBP-DLNGFR-W was then
compared with pHRSIN-SE-P2A-SBP-DLNGFR-W (encoding GFP-P2A-SBP-DLNGFR under the SFFV promoter; B). Transduced cells are GFP+/LNGFR-
Antibody-Free Magnetic Cell Sorting
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6–24 hrs after activation was performed by spinoculation at 800 g
for 1–2 hrs in a benchtop centrifuge.
Flow cytometry
293Ts were harvested with enzyme-free cell dissociation buffer
and Dynabeads Human T-Activator CD3/CD28 beads were
removed from primary human CD4+ T cells using a DynaMag-2
magnet (Invitrogen). Typically 26105 washed cells were incubated
for 30 mins in 100 mL PBS with the indicated fluorochrome-
conjugated antibody or streptavidin-APC. All steps were per-
formed on ice or at 4uC and stained cells were analysed
immediately or fixed in PBS/1% paraformaldehyde. Viability
was assessed using forward and side scatter, and absolute cell
numbers determined using CytoCount beads (Dako) as a reference
population according to the manufacturer’s instructions.
Antibody-free magnetic cell sorting
For pilot experiments in transfected 293Ts (Figure 1), washed
cells were harvested with enzyme-free dissociation buffer and
filtered (50 mm) to remove clumps. For selection using Dynabeads
Biotin Binder (Invitrogen), cells were resuspended in Incubation
Buffer (IB; PBS without calcium/magnesium, 2 mM EDTA, 0.1%
BSA) at 107 cells/ml and incubated with Dynabeads at a bead-to-
total cell ratio of 4:1 for 30 mins at 4uC. Bead-bound cells were
APC+ (dashed circles). Background staining of untransfected/unstransduced controls is shown (grey). Finally, primary human CD4+ T cells were
transduced with the optimised pHRSIREN-S-SBP-DLNGFR-W and pHRSIN-SE-P2A-SBP-DLNGFR-W lentivectors (C) encoding 2 different shRNAs and 2
different exogenous genes. Following selection with Dynabeads Biotin Binder, purity was assessed by staining with anti-LNGFR-PE (D). Each datapoint
represents % LNGFR+ for a different construct (shRNA or exogenous gene) and means and SEMs are shown. Viability and functional activity of
selected (expressing a control shRNA) and mock (unselected) cells were compared (E). Viability was measured 4 days after selection, and cells either
rested or re-stimulated with CD3/CD28 Dynabeads. Resting and re-stimulated cells were stained with CD69-APC (day 2) and enumerated using
CytoCount beads (days 1–3). CD69 expression by resting (grey) versus re-stimulated mock (pale blue) and selected (pink) cells is shown. Fold-
increases in viable cell numbers following re-stimulation (proliferation) were calculated using day 1 as a baseline. Experiments were conducted in
triplicate and means and SEMs are shown. cPPT – central polypurine tract; RRE – Rev response element; * – packaging signal; LTR – long terminal
repeat; WPRE – Woodchuck Hepatitis Virus post-transcriptional regulatory element.
doi:10.1371/journal.pone.0111437.g003
Figure 4. Antibody-Free Magnetic Cell Sorting of 293 T cells following CRISPR/Cas9 genome editing. 293Ts were transiently transfected
with pSpCas9(BB)-P2A-SBP-DLNGFR (encoding gRNA to b2 m and Cas9-P2A-SBP-DLNGFR under the CBh promoter; A) and stained with anti-MHC-I-
AF647 before (blue) or after (red) selection with Dynabeads Biotin Binder (B). Transfected cells with b2 m knockouts are MHC-I low (dashed boxes).
Background staining of untransfected controls is shown (light grey).
doi:10.1371/journal.pone.0111437.g004
Antibody-Free Magnetic Cell Sorting
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selected using a DynaMag-2 (Invitrogen) then released from the
beads by incubation in IB supplemented with 2 mM biotin for
15 mins at room temperature (RT) and analysed by flow
cytometry. For selection using Streptavidin MicroBeads (Miltenyi)
cells were resuspended in IB at 2.56107 cells/ml and incubated
with MicroBeads at a bead-to-total cell ratio of 10 ml:107 cells for
30 mins at 4uC. Bead-bound cells were selected using an MS
Column and MACS Separator (Miltenyi) and analysed by flow
cytometry without MicroBead removal. For selection of trans-
duced primary human CD4+ T cells, Dynabeads Human T-
Activator CD3/CD28 beads were first removed according to the
manufacturer’s instructions. An optimised protocol for Antibody-
Free Magnetic Cell Sorting using Dynabeads Biotin Binder is
supplied (Protocol S1). For functional assays in primary human
CD4+ T cells, mock (unselected) cells were subjected to a sham
selection procedure of equivalent duration, including incubation
with Dynabeads Biotin Binder.
Results and Discussion
The 38 amino acid SBP may be displayed at the cell
surface by fusion with the truncated LNGFR
The 38 amino acid SBP is a high-affinity streptavidin-binding
peptide tag previously used for purification of recombinant
proteins and, more recently, as an affinity tag in live cells for the
synchronisation of secretory traffic [10,11,19]. To express the 38
amino acid SBP at the cell surface, we fused it to the N-terminus of
the truncated LNGFR (SBP-DLNGFR; Figure 1B). 293Ts trans-
fected with this construct were readily stained with streptavidin-
APC in the absence of permeabilisation, indicating expression of
SBP-DLNGFR at the plasma membrane and accessibility for
streptavidin binding (Figure 1C). SBP-DLNGFR was also readily
detected using an LNGFR-specific antibody (Figure 1D). LNGFR
is a 399 amino acid Type I transmembrane cell surface
glycoprotein member of the Tumour Necrosis Factor Receptor
superfamily [20]. The truncated LNGFR, which lacks a cytoplas-
mic domain, has been previously used as a non-functional cell
surface marker for antibody-based cell selection, including in vitro
and in vivo for purification of transduced human lymphocytes in
the setting of allogeneic bone marrow transplantation [21,22]. The
level of cell surface streptavidin-binding peptide expression
achieved was critically dependent on the fusion protein chosen,
since preliminary experiments using the 38 amino acid SBP fused
to the HLA-A2 heavy chain, or the streptavidin-binding Nano-tag
peptide fused to a membrane-targeted red fluorescent protein
construct [9,23], showed poor staining at the surface of transfected
cells.
Cells expressing SBP-DLNGFR may be selected using
streptavidin-conjugated magnetic beads
To test whether SBP-DLNGFR could be used for cell selection,
we incubated transfected 293Ts with streptavidin-conjugated
magnetic beads. Bead-bound cells were washed, and then either
analysed directly by flow cytometry, or released from the beads by
incubation with excess biotin. Selected cells were markedly
enriched for SBP-DLNGFR expression, and comparable results
were achieved using streptavidin-conjugated beads from 2
different manufacturers (Figure 1D). Dynabeads Biotin Binder
were used for subsequent experiments at an optimised bead-to-
target cell ratio of 10:1. Although the 38 amino acid SBP interacts
strongly with streptavidin (nanomolar Kd, comparable to a strong
antibody-antigen interaction), it is readily out-competed by biotin
(femtomolar Kd, one of the strongest non-covalent interactions
known) [10,19,24,25]. In practice, bound cells could be completely
released from streptavidin-conjugated beads by incubation with
2 mM biotin for as little as 15 mins. Magnetic selection of cells
expressing cell surface streptavidin (using bead-bound anti-
streptavidin antibody) or co-expressing a cell surface biotin-
acceptor peptide with the E. coli biotin ligase BirA (using
streptavidin-conjugated beads) has been previously described
[26,27,28], as has FACS of cells expressing a cell surface biotin-
mimetic peptide (using fluorochrome-conjugated streptavidin)
[29]. Conversely, this is the first report of the use of a cell surface
streptavidin binding peptide for magnetic cell sorting, combining
the advantages of bead-based cell isolation with the ability to
release beads from selected cells by competition with biotin.
SBP-DLNGFR affinity purification may be used to isolate
cells expressing an shRNA or exogenous gene of interest
To select genetically modified mammalian cells using SBP-
DLNGFR affinity purification, we co-expressed the fusion protein
with an exogenous gene or shRNA on the same lentiviral
construct. As proof of principle, SBP-DLNGFR was subcloned
into lentiviral vectors encoding either GFP or an shRNA to b2-
microbglobulin (b2 m). b2 m is an essential subunit of MHC class
I molecules and its depletion may therefore be detected by
reduction of cell surface MHC class I alleles such as HLA-A2 [30].
Co-expression of SBP-DLNGFR with GFP (Figure 2A) or shRNA
to b2 m (Figure 2B) was confirmed by transient transfection of
293Ts, and similar results were obtained using VSVg-pseudotyped
lentiviral particles (Figures 2A and 2B). The selection of cells
genetically modified ex vivo remains a significant methodological
challenge for human gene therapy. As well as the treatment of
monogenic disorders such as ADA-SCID (adenosine deaminase
deficiency resulting in severe combined immunodeficiency) major
research efforts have focussed on cancer immunotherapy using
engineered T cells expressing tumour-specific T cell receptor a
and b chains (abTCRs) or chimeric antigen receptors (CARs), and
the production of HIV-resistant CD4+ T cells through, for
example, disruption or downregulation of the CCR5 HIV co-
receptor [31,32,33]. We therefore decided to test whether
magnetic selection for SBP-DLNGFR could be used to purify
genetically modified primary human CD4+ T lymphocytes
expressing an exogenous gene or shRNA of interest. Indeed,
following lentiviral transduction and SBP-DLNGFR affinity
purification, pure populations of cells either high in GFP or low
in HLA-A2 were successfully isolated (Figures 2C and 2D).
Antibody-free magnetic cell sorting yields .99% pure
populations of primary human CD4+ T cells in ,1 hr
Expression of SBP-DLNGFR from the PGK promoter was
noted to vary markedly according to the activation state of
transduced T cells (Figure 3A). PGK encodes the glycolytic
enzyme phoshpoglycerokinase, and glycolysis is known to be
highly regulated in T cells [34]. To optimise the system for
selecting primary human lymphocytes, we therefore introduced
the SFFV promoter to drive expression of SBP-DLNGFR either as
a single cistron (pHRSIREN-S-SBP-DLNGFR-W) or co-translat-
ed with an exogenous gene of interest via a P2A ‘‘self-cleaving’’
peptide linker for bicistronic expression (pHRSIN-SE-P2A-SBP-
DLNGFR-W). These modifications increased SBP-DLNGFR
expression without compromising levels of the co-expressed gene
or shRNA of interest (Figure 3B). Expression levels were critically
dependent on both the WPRE and the promoter strategy used,
with inferior results obtained using the EF1a promoter, ECMV
IRES or dual SFFV promoter systems, or when the WPRE was
absent or alternatively located. The SFFV promoter is known to
Antibody-Free Magnetic Cell Sorting
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provide high-level transgene expression in primary human
haematopoietic cells [14] and 2A peptides have been shown to
enable stoichiometric co-expression of multiple cistrons across
different organisms and cell types [15,35]. These small viral
peptide sequences are co-translationally ‘‘cleaved’’ in a process
known as ‘‘ribosomal skipping’’ in which formation of a glycyl-
prolyl peptide bond at the C-terminus of the 2A peptide is
‘‘skipped’’ without interrupting translation of the downstream
polypeptide [36]. To test the optimised vectors (Figure 3C), we
transduced primary human CD4+ T cells using 4 different
constructs (expressing 2 different shRNAs and 2 different
exogenous genes). From a starting purity of 31.0%, the average
purity of selected cells was 99.2% (Figure 3D). We have not
observed any functional deficits in a wide range of downstream
applications (including viability, expression of activation markers,
and proliferation; Figure 3E), and the Antibody-Free Magnetic
Cell Sorting procedure (from incubation with magnetic beads
through release with biotin) may be readily completed (including
multiple samples) in ,1 hr.
Antibody-free magnetic cell sorting allows isolation of
cells following CRISPR/Cas9 genome editing
The type II bacterial CRISPR ‘‘immune system’’ has recently
been re-purposed to allow facile site-specific genome engineering
in mammalian cells by co-expression of the Cas9 nuclease with a
short gRNA [18,37,38]. Complementary base-pairing through the
gRNA recruits the gRNA/Cas9 complex to a target sequence in
the genomic DNA, where it introduces double-strand DNA
breaks. Where the target sequence is in an open reading frame
(ORF), repair of these breaks by non-homologous end joining
frequently introduces short insertions and deletions (InDels),
leading to frameshifts and/or premature stop codons and
knockout of the targeted gene. Alternatively, if an exogenous
DNA repair template is also supplied, homology-directed repair
may be utilised to copy this template to the cut target sequence,
allowing the introduction of specific nucleotide changes or ‘‘knock-
in’’ of exogenous sequences. As compared with the requirement
for persistent expression of an shRNA or exogenous gene of
interest, an advantage of CRISPR/Cas9 genome editing is that
transient expression of the Cas9 nuclease and site-specific gRNA
plus/minus DNA repair template may be used to introduce
permanent genetic modifications. Conversely, this approach
makes selection of genetically modified cells using antibiotics or
FACS challenging, since expression from the CRISPR/Cas9
vectors is time-limited. To test whether Antibody-Free Magnetic
Cell Sorting could be used to isolate cells following CRISPR/Cas9
genome editing, we transfected 293Ts with a vector encoding a
gRNA targeting the 59 end of the b2 m gene and SBP-DLNGFR
co-translated with Cas9 via a P2A peptide linker (Figure 4A). As
with shRNA knockdown, knockout of the b2 m gene may be
detected by reduction in cell surface MHC class I (MHC-I).
Following Antibody-Free Magnetic Cell Sorting, MHC-I low cells
were markedly enriched (Figure 4B). The ability to enrich
genetically modified cells may be particularly helpful if the
phenotype associated with the genetic modification is either
unknown or unsuitable for subsequent selection by FACS, and/or
in situations where difficult-to-transfect cells are used, resulting in
a low frequency of cells with the desired genetic modification and
the necessity to screen multitudinous clones.
Conclusions
Antibody-Free Magnetic Cell Sorting is a novel, efficient way to
select transfected or transduced mammalian cells. Selection is
readily scalable to almost any cell number and may be completed
in ,1 hr (plus cell washes). No antibody is required, allowing
rapid one-step affinity purification and making the process
extremely cost-effective. Enrichment to .99% purity is routinely
achieved and, following release with biotin, cells are left
‘‘untouched’’ by residual beads or antibody-antigen complexes.
As well as providing a useful tool for life sciences research, the
system may be used to select genetically modified cells for human
gene therapy applications. Potential applications of Antibody-Free
Magnetic Cell Sorting are not limited to the expression of shRNAs
or exogenous genes of interest, and CRISPR/Cas9 genome
editing. For example, we are currently developing vectors for one-
step magnetic selection of cells following infection with an HIV
reporter virus [39], and expression of SBP-DLNGFR may be used
as a reporter gene for selection of cells in which a promoter of
interest is active in vitro or in vivo.
Supporting Information
Protocol S1 Antibody-Free Magnetic Cell Sorting.
(PDF)
Sequence S1 Codon-optimised SBP-DLNGFR construct.
(PDF)
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